Ipsen S.A. (LON:0MH6)

London flag London · Delayed Price · Currency is GBP · Price in EUR
120.80
+0.85 (0.71%)
At close: Dec 19, 2025
9.48%
Market Cap8.65B
Revenue (ttm)3.22B
Net Income (ttm)383.94M
Shares Outn/a
EPS (ttm)4.60
PE Ratio22.54
Forward PE10.47
Dividend1.18 (0.98%)
Ex-Dividend DateJun 4, 2025
Volume38,133
Average Volume45,408
Open119.50
Previous Close119.95
Day's Range116.10 - 120.50
52-Week Range88.05 - 131.60
Beta0.14
RSI40.39
Earnings DateFeb 12, 2026

About Ipsen

Ipsen S.A., a biopharmaceutical company, develops and commercializes medicines in the areas of oncology, rare disease, and neuroscience worldwide. Its oncology products include Somatuline for the treatment of neuroendocrine tumors and acromegaly; Cabometyx, a tyrosine kinase inhibitor to treat second line pancreatic and extra-pancreatic neuroendocrine tumors; Onivyde, an irinotecan liposome injection for the treatment of pancreatic cancer; Decapeptyl for the treatment of advanced metastatic prostate cancer; Tazverik, a chemotherapy-free EZH2a i... [Read more]

Industry Pharmaceutical Preparations
Founded 1929
Employees 5,358
Stock Exchange London Stock Exchange
Ticker Symbol 0MH6
Full Company Profile

Financial Performance

In 2024, Ipsen's revenue was 3.57 billion, an increase of 8.11% compared to the previous year's 3.31 billion. Earnings were 345.90 million, a decrease of -46.32%.

Financial numbers in EUR Financial Statements

News

There is no news available yet.